Skip to main content
. 2019 Mar 14;7:e6612. doi: 10.7717/peerj.6612

Table 1. Baseline characteristics of the NSCLC patients.

Characteristic Study group (408) Control group (1,465) P-value
Age <0.001
 <60 years 275 (67.4) 724 (49.4)
 ≥60 years 133 (32.6) 741 (50.6)
Gender 0.002
 Male 315 (77.2) 1,015 (69.3)
 Female 93 (22.8) 450 (30.7)
T category 0.705
 T1 52 (12.7) 173 (11.8)
 T2 155 (38.0) 533 (36.4)
 T3 76 (18.6) 309 (21.1)
 T4 125 (30.6) 450 (30.7)
N category 0.370
 N0 105 (25.7) 377 (25.7)
 N1 45 (11.0) 145 (9.9)
 N2 150 (36.8) 601 (41.0)
 N3 108 (26.5) 342 (23.3)
Pathological type 0.298
 Squamous 133 (32.6) 519 (35.4)
 Non-squamous 275 (67.4) 946 (64.6)
ALT or AST level <0.001
 <40 U/L 351 (86.0) 1,350 (92.2)
 ≥40 U/L 57 (14.0) 115 (7.8)
Hepatitis virus 0.039
 Present 37 (9.1) 188 (12.8)
 Absent 371 (90.9) 1,277 (87.2)
Diabetes mellitus 0.015
 Yes 45 (11.0) 107 (7.3)
 No 363 (89.0) 1,358 (92.7)
BMI <0.001
 <25 kg/m2 240 (58.8) 1,183 (80.8)
 ≥25 kg/m2 168 (41.2) 282 (19.2)
Surgery 0.235
 Yes 157 (38.5) 517 (35.3)
 No 251 (61.5) 948 (64.7)
Chemotherapy 0.654
 Yes 372 (91.2) 1,325 (90.4)
 No 36 (8.8) 140 (9.6)
Radiotherapy 0.360
 Yes 96 (23.5) 328 (22.4)
 No 312 (76.5) 1,137 (77.6)

Note:

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index.